Abraxis BioScience, Inc. Completes Enrollment of Pivotal Phase III Advanced Lung Cancer Study Evaluating ABRAXANE(R) Vs Taxol(R)

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced today that the company has completed patient enrollment of a pivotal, phase III clinical study comparing the company’s chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) with Taxol® (paclitaxel) injection, both in combination with carboplatin, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The study, which is being conducted at 111 sites globally, includes 1,050 patients and is being led by principal investigator Dr. Mark Socinski at the University of North Carolina Lineberger Comprehensive Cancer Center. It is one of the largest NSCLC clinical studies to complete enrollment.

Back to news